We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Jun 2020 - 09 Jun 2020
Virtual Venue
08 Jun 2020 - 11 Jun 2020
Virtual Venue

Corgenix Diagnostic Ebola Test Research Earns Abstract Award

By LabMedica International staff writers
Posted on 01 Aug 2014
Print article
The Best Annual Meeting Abstract Award is given by the AACC Critical and Point-of-Care Testing Division in recognition of outstanding research for abstracts submitted and posters presented at the AACC annual meeting.

The Ebola research award and Lassa fever oral abstract of Corgenix Medical (Broomfield, CO, USA) receive the award recognized for its high quality poster abstract, “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection,” presented at the AACC conference. Douglass Simpson, BS, MS, Corgenix president and CEO comments, “We’re pleased to accept this prestigious award, and we must also recognize our academic, research, and industry partners at the Viral Hemorrhagic Fever Consortium (VHFC), who have helped to make this possible. We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa, and other biologic agents. Rapid, accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats.”

Corgenix and the VHFC were recently awarded a three-year, USD 2.9 million National Institutes of Health (NIH) grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV rapid diagnostic test for the Lassa fever virus.

The current Ebola outbreak in West Africa is the largest ever recorded. Mr. Simpson said that it is clear that point-of-care (POC) testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola, and Marburg.

Corgenix is also presenting an oral abstract titled “Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone.” The study was conducted to better identify and treat patients with Lassa, which can be difficult to distinguish from other illnesses such as malaria. Study results are being presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry.

Related Links:

Corgenix Medical
National Institutes of Health

Print article



view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.